It is noteworthy that no ruthenium complex was specifically reported for the treatment of HER2+ breast cancer, so that reports of ruthenium complexes for hormone receptor negative breast cancer therapy are limited to TNBC therapy. Here, ERBB2 is linked to breast cancer.